<p>David S. Hong, MD, discusses the results from the phase II innovaTV 201 trial looking at the antibody-drug conjugate tisotumab vedotin in patients with metastatic or recurrent cervical cancer.</p>
David S. Hong, MD, deputy director of the department of investigational cancer therapeutics and associate vice president at The University of Texas MD Anderson Cancer Center, discusses the results from the phase II innovaTV 201 trial looking at the antibody-drug conjugate tisotumab vedotin in patients with metastatic or recurrent cervical cancer.
The phase I study led to a recommended phase II dose of 2 mg/kg every 3 weeks, according to Hong. This dose showed activity across a number of histologies, but in particular, showed promising results in this patient population with cervical cancer.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More